1209465-72-4

Upstream product

• 137281-39-1 4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl )ethyl]benzoic acid 
• 204257-42-1 (S)-4-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)-5-(benzyloxy)-5-oxopentanoic acid 
• 1209465-71-3 (S)-1-benzyl 5-(2,5-dioxopyrrolidin-1-yl) 2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate 
• 1209465-70-2 C₂₀H₁₉N₇O₅ 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 

Relevant academic research and scientific papers

Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma

Pemetrexed (PMX) is a multi-targeted antifolate drug used for the treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer. Hyaluronan (HA) in blood is well known as a disease marker of MPM. We synthesized PMX-conjugated hyaluronan

PEMETREXED-CONJUGATED HYALURONAN

PROBLEM TO BE SOLVED: To provide a compound effective in the treatment of disseminative tumor, and to provide pharmaceutical compositions comprising the compound. SOLUTION: Provided is a pemetrexed-conjugated hyaluronan in which pemetrexed is covalently b

BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compoun